医学
粒细胞巨噬细胞集落刺激因子
剑
肿瘤科
放射治疗
肺
粒细胞
癌症
肺癌
癌症研究
内科学
病理
细胞因子
计算机科学
操作系统
作者
Jianjiao Ni,Xiaofei Wang,Lin Wu,Xinghao Ai,Qian Chu,Cheng‐Bo Han,Xiaorong Dong,Yue Zhou,Yechun Pang,Zhengfei Zhu
标识
DOI:10.1038/s41467-024-51807-7
摘要
This single-arm, multicenter, phase 2 trial (NCT04106180) investigated the triple combination of sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastatic non-small cell lung cancer (NSCLC). With a median follow-up of 32.1 months, 18 (36.7%, 90% CI 25.3%–49.5%) of the 49 evaluable patients had an objective response, meeting the primary endpoint. Secondary endpoints included out-of-field (abscopal) response rate (ASR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). The ASR was 30.6% (95% CI 18.3%–45.4%). The median PFS and OS were 5.9 (95% CI 2.5–9.3) and 18.4 (95% CI 9.7–27.1) months, respectively. Any grade and grade 3 TRAEs occurred in 44 (86.3%) and 6 (11.8%) patients, without grade 4–5 TRAEs. Moreover, in pre-specified biomarker analyses, SBRT-induced increase of follicular helper T cells (Tfh) in unirradiated tumor lesions and patient's blood, as well as of circulating IL-21 levels, was found associated with improved prognosis. Taken together, the triple combination therapy was well tolerated with promising efficacy and Tfh may play a critical role in SBRT-triggered anti-tumor immunity in metastatic NSCLC. Combinations of radiotherapy and immune checkpoint inhibitors have been explored for the treatment of patients with non-small cell lung cancer (NSCLC). Here the authors report the results of a phase 2 trial of sintilimab (anti-PD1) in combination with stereotactic body radiotherapy and GM-CSF in metastatic NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI